Benign Prostatic Hyperplasia Surgical Devices Market By Device Type (Laser-Based Surgical Devices, Mechanical Devices, Radiofrequency Devices, Transurethral Resection of the Prostate (TURP) Devices, Prostatic Urethral Lift Devices), By Procedure Type (Minimally Invasive Surgery, Open Surgery), By End-User (Hospitals, Ambulatory Surgery Centers, Urology Clinics), and By Region; Global Insights & Forecast (2024 - 2030)

As per Intent Market Research, the Benign Prostatic Hyperplasia Surgical Devices Market was valued at USD 5.0 billion in 2023 and will surpass USD 8.9 billion by 2030; growing at a CAGR of 8.5% during 2024 - 2030.

The Benign Prostatic Hyperplasia (BPH) surgical devices market has witnessed significant growth driven by the increasing prevalence of BPH among aging populations and the advancements in minimally invasive surgical techniques. BPH is a common condition in older men, characterized by the enlargement of the prostate gland, which obstructs the flow of urine. As the global geriatric population increases, the demand for effective treatment options has risen, resulting in the growing use of surgical devices to alleviate symptoms and improve the quality of life. The development of advanced surgical devices has made BPH treatment more effective and less invasive, offering patients shorter recovery times and fewer complications.

The market is also being influenced by technological innovations, such as laser-based devices and prostatic urethral lift devices, which have transformed BPH surgery. These devices are designed to provide more precise and effective treatment with minimal discomfort to the patient. As awareness of BPH and its symptoms continues to rise, the demand for surgical interventions is expected to grow, fueling the expansion of the market. Additionally, healthcare facilities are increasingly adopting advanced surgical technologies to enhance patient outcomes and streamline procedures.

Laser-Based Surgical Devices Offer Significant Growth Potential

Laser-based surgical devices are among the leading treatment options in the BPH surgical devices market. These devices utilize focused laser energy to vaporize or shrink the excess prostate tissue, improving urine flow and alleviating the symptoms of BPH. Laser-based procedures, such as Holmium Laser Enucleation of the Prostate (HoLEP), are known for their precision and ability to target tissue while minimizing bleeding, which is a common concern in traditional prostate surgeries.

The growth of laser-based devices is fueled by the increasing preference for minimally invasive procedures, which offer shorter recovery times and lower complication rates. Laser technology also provides greater control and flexibility, making it a preferred choice for patients who seek effective and less traumatic treatment options. As the demand for minimally invasive BPH treatments rises, the adoption of laser-based devices is expected to continue its upward trajectory, contributing significantly to the market’s growth.

Minimally Invasive Surgery Dominates Procedure Type

Minimally invasive surgery is the dominant procedure type in the Benign Prostatic Hyperplasia surgical devices market. With the advancements in technology, minimally invasive techniques, such as laser therapy, transurethral resection, and prostatic urethral lift procedures, are gaining popularity due to their ability to treat BPH with minimal disruption to the patient’s body. These procedures are associated with reduced risk of complications, shorter hospital stays, and quicker recovery times compared to traditional open surgery.

Minimally invasive surgeries are becoming the standard for BPH treatment as they offer patients a more comfortable and efficient option. The widespread adoption of minimally invasive surgical devices is expected to continue, driven by the need for cost-effective treatments and the demand for patient-friendly procedures. As healthcare providers focus on improving patient outcomes and reducing healthcare costs, minimally invasive surgery will likely remain the preferred option for BPH patients.

Hospitals Lead as the Primary End-User

Hospitals are the leading end-user for BPH surgical devices due to the need for specialized medical staff, advanced facilities, and the ability to perform complex procedures. Hospitals have the infrastructure to support a wide range of surgical procedures, including laser-based, mechanical, and radiofrequency treatments for BPH. Moreover, hospitals are often equipped with the latest technologies, which make them the preferred choice for patients seeking comprehensive care and advanced treatment options.

In addition to hospitals, ambulatory surgery centers and urology clinics are also contributing to the market’s growth, as they offer outpatient services for BPH treatment. These facilities provide a more cost-effective solution for patients seeking treatment for BPH, with shorter wait times and less expensive procedures. However, hospitals remain the primary setting for the more complex BPH surgeries, ensuring their dominance in the market.

North America Dominates Benign Prostatic Hyperplasia Surgical Devices Market Due to Innovation

North America leads the Benign Prostatic Hyperplasia Surgical Devices Market, fueled by technological advancements in minimally invasive surgical techniques. The adoption of laser-based surgical devices and prostatic urethral lift devices has revolutionized patient outcomes in the region. Strong healthcare infrastructure and favorable reimbursement policies contribute to market growth. The region's aging population, coupled with high awareness about prostate health, drives demand for innovative surgical solutions. Leading medical device manufacturers headquartered in the U.S. further ensure the availability of state-of-the-art technologies, reinforcing North America's market dominance.

Competitive Landscape

The competitive landscape of the Benign Prostatic Hyperplasia surgical devices market is highly dynamic, with numerous medical device manufacturers developing innovative products to meet the growing demand for effective BPH treatments. Key players in the market include companies such as Boston Scientific, Medtronic, and Olympus Corporation, which offer a wide range of surgical devices designed to treat BPH. These companies are focused on expanding their product portfolios with advanced technologies, such as laser-based devices, prostatic urethral lift devices, and radiofrequency devices.

In addition to established players, emerging companies and start-ups are also entering the market, driving competition and contributing to innovation. The market is expected to continue evolving with the introduction of new devices that offer improved safety, efficiency, and patient comfort. As the BPH surgical devices market grows, manufacturers will need to focus on developing cost-effective solutions that meet the needs of healthcare providers and patients, while maintaining high standards of quality and performance.

Recent Developments:

• In December 2024, Medtronic received FDA approval for a next-generation transurethral resection device for BPH treatment.
• In November 2024, Boston Scientific launched an advanced laser therapy device aimed at improving outcomes in BPH surgeries.
• In October 2024, Olympus Corporation introduced a new robotic system designed to assist in minimally invasive BPH surgery.
• In September 2024, Urologix announced the successful clinical trial results for a new radiofrequency-based BPH treatment device.
• In August 2024, Lumenis Ltd. unveiled a cutting-edge Holmium laser system designed specifically for BPH patients with enlarged prostates.

List of Leading Companies:

• Boston Scientific Corporation
• Olympus Corporation
• Medtronic PLC
• Lumenis Ltd.
• Urologix, Inc.
• Convergent Laser Technologies
• Cook Medical
• EDAP TMS S.A.
• Teleflex Incorporated
• Baxter International Inc.
• Coloplast A/S
• Hill-Rom Holdings, Inc.
• Intuitive Surgical, Inc.
• Stryker Corporation
• Smith & Nephew plc

Report Scope: